Dipeptidyl Peptidases are widely distributed exopeptidases that possess central role in proteolysis.The DPP-IV family of dipeptidyl peptidases, which also includes DPP-7, DPP-8, DPP-9, fibroblast activation protein, and others, cleaves the peptide bond after the penultimate proline residue and has a large number of drug targets.
A serine protease known as DPP-IV (DPP4 or CD26) has been found on a number of immune cells and epithelial cells from different organs. A catalytically active soluble form of the enzyme is also found in several bodily fluids in addition to the membrane-bound enzyme. The N-termini of numerous chemokines, neuropeptides, and hormones are cleaved off by both variants, releasing dipeptides. By focusing on various substrates, DPP IV is essential for the regulation of the immune system, inflammation, oxidative stress, cell adhesion, and apoptosis. Drugs that inhibit DPP IV are frequently used to lower blood sugar.
DPP8 and DPP9 exhibit DPPIV-like activity and have a high degree of sequence similarity. Intracellular N-terminal dipeptidyl peptidases DPP8 and DPP9 (preferentially postproline) have been linked to pathophysiological roles in cancer biology and immune response.
| Structure | Cat No. | Product Name | CAS No. | Product Description |
|---|---|---|---|---|
|
V2633 | Saxagliptin hydrate | 945667-22-1 | Saxagliptin hydrate (also known as BMS-477118 hydrate, Onglyza hydrate, BMS 477118 hydrate, BMS477118 hydrate; brand name: Onglyza), the hydrate form of Saxagliptin, is a potent,orally bioactive, selective and reversible DPP4 (dipeptidyl peptidase-4) inhibitor with IC50 of 26 nM. |
|
V15698 | Talabostat mesylate | 150080-09-4 | Talabostat mesylate, the mesylate salt of Talabostat (PT-100; PT100 Val-boroPro), is an orally available inhibitor of dipeptidyl peptidase (DPP4, DPP8, and DPP9) with a Ki of 0.18 nM. |
|
V0742 | Linagliptin | 668270-12-0 | Linagliptin (formerly known as BI-1356; trade names Tradjenta and Trajenta)is a xanthine-based, highly potent, selective, andcompetitive DPP-4 inhibitor with potential anti-diabetic activity. |
|
V5081 | Puromycin Aminonucleoside (NSC-3056) | 58-60-6 | Puromycin aminonucleoside (formerly known as NSC 3056; PAN, NSC-3056), the aminonucleoside portion of the antibiotic puromycin, is commonly used in nephrosis animal models as well as in the study of human glomerular disease, and glomerular function and morphology. |
|
V2771 | Omarigliptin | 1226781-44-7 | Omarigliptin (formerly known as MK-3102; MK3102) is a potent, selective, oral and long-acting inhibitor ofDPP-4 (dipeptidyl peptidase 4) with antidiabetic effects. |
|
V4104 | Anagliptin (SK-0403) | 739366-20-2 | Anagliptin (formerly known as SK0403) is a novel, potent, orally bioactive, highly selective inhibitor of DPP-4 (dipeptidyl peptidase 4)with anIC50of 3.8 nM. |
|
V0746 | Trelagliptin (SYR472; Zafatek) | 865759-25-7 | Trelagliptin (formerly also known as SYR-472; trade name Zafatek) is a potent, highly selective, long-acting DPP-4 (dipeptidyl peptidase-4) inhibitor with potential anti-hyperglycemicactivity. |
|
V2634 | Teneligliptin hydrobromide | 906093-29-6 | Teneligliptin HBr (formerly MP-513; MP513; trade name Tenelia in Japan), the hydrobromide salt of Teneligliptin, is a novel, potent, orally bioavailable and long-lasting dipeptidyl peptidase-4 (DPP-4) inhibitor; Teneligliptin is an approved drug for the treatment of type 2 diabetes mellitus in Japan. |
|
V0744 | Saxagliptin (BMS477118; Onglyza) | 361442-04-8 | Saxagliptin (formerly also known as BMS-477118; brand name: Onglyza) is a potent, orally bioactive, selective and reversible DPP-4 (dipeptidyl peptidase-4) inhibitor with potential anti-hyperglycemic activity. |
|
V2555 | Trelagliptin succinate (SYR-472) | 1029877-94-8 | Trelagliptin succinate(also known as SYR-472 succinate) is a potent, highly selective, long-acting DPP-4 (dipeptidyl peptidase-4) inhibitor under development by Takeda for the treatment of type 2 diabetes (T2D). |
|
V0741 | Sitagliptin phosphate monohydrate | 654671-77-9 | Sitagliptin phosphate (formerly also known as MK-431; trade name Januvia; Xelevia; Janumet) monohydrate, the phosphate and hydrated form of Sitagliptin which is an antihyperglycemic agent and antidiabetic drug, is a potent, triazolopyrazine-based, andorally bioavailable inhibitor of DPP-IV (dipeptidyl peptidase-4) with IC50 of 19 nM in Caco-2 cell extracts. |
|
V0743 | Vildagliptin (NVP LAF 237; DSP7238; LAF237) | 274901-16-5 | Vildagliptin (formerly also known as NVP LAF237; DSP-7238; LAF-237; trade name: Zomelis) is an potent and orally bioavailable anti-diabetic drug that acts as an inhibitor of DPP-4 (dipeptidyl peptidase 4) with an IC50 of 2.3 nM. |
|
V2553 | Alogliptin benzoate (SYR-322) | 850649-62-6 | Alogliptin benzoate (SYR-322 benzoate; Nesina; Kazano, Oseni), the benzoate salt of alogliptin, is a novel, potent, orally bioavailable, and selective inhibitor of DPP-4 (serine protease dipeptidyl peptidase IV) withanti-diabetic effects. |
|
V4388 | SITAGLIPTIN | 486460-32-6 | Sitagliptin (formerly also known as MK-431; trade name Januvia), an antihyperglycemic agent and a antidiabetic drug, is a potent, orally bioavailable inhibitor of DPP-IV (dipeptidyl peptidase-4) with IC50 of 19 nM in Caco-2 cell extracts. |
|
V0745 | Alogliptin (SYR322) | 850649-61-5 | Alogliptin (formerly also known as SYR-322; trade names Nesina; Kazano, Oseni) is a novel, potent, orally bioavailable, and selective inhibitor of DPP-4 (serine protease dipeptidyl peptidase IV) with potential anti-hyperglycemic activity. |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
